Baroreflex

A new consensus statement from the Heart Failure Society of America outlines how device-based therapies can help certain patients with HF and how HF devices can be integrated into clinical workflow.

Baroreflex activation therapy plus optimal medical therapy improved quality of life at 2 years in patients with HF with reduced ejection fraction compared with optimal medical therapy alone, researchers reported.

CVRx Inc. announced the FDA approved its revised instructions for use for its baroreflex activation therapy device incorporating clinical data from the BeAT-HF randomized clinical trial.